Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

P300 topography in Alzheimer's disease

L E Holt1, A Raine, G Pa

  • 1Department of Psychology, University of Southern California, Los Angeles 90089-1061, USA.

Psychophysiology
|May 1, 1995
PubMed
Summary

This study found distinct P300 brainwave patterns in Alzheimer's disease (AD) patients compared to healthy controls. Alzheimer's patients showed altered P300 topography, indicating potential diagnostic markers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma pTau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.

medRxiv : the preprint server for health sciences·2026
Same author

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia.

The journal of prevention of Alzheimer's disease·2023
Same author

Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about 'Reasonable and Necessary'?

The journal of prevention of Alzheimer's disease·2023
Same author

Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.

The journal of prevention of Alzheimer's disease·2022
Same author

Editorial: Aducanumab Trials EMERGE But Don't ENGAGE.

The journal of prevention of Alzheimer's disease·2022
Same author

A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2022

Area of Science:

  • Neuroscience
  • Cognitive Neuroscience
  • Neurology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Understanding the neurophysiological underpinnings of AD is crucial for early diagnosis and intervention.
  • Scalp P300 event-related potential (ERP) topography has been explored as a potential biomarker for neurological conditions.

Purpose of the Study:

  • To determine if P300 scalp topography can differentiate individuals with Alzheimer's disease (AD) from healthy controls.
  • To test the hypothesis that AD patients exhibit maximal P300 amplitude frontally and reduced amplitude parietally and on the left hemisphere.

Main Methods:

  • An auditory oddball paradigm was employed.
  • P300 amplitude was measured across frontal, central, parietal, and occipital sites in both hemispheres and midline.

Related Experiment Videos

  • 26 AD subjects were compared to 26 age-, sex-, handedness-, and education-matched controls.

    • Main Results:

    • Significant differences in P300 distribution were observed between AD patients and controls.
    • Controls showed maximal P300 amplitude over parietal areas.
    • AD subjects displayed maximal P300 amplitude frontally, with the most substantial reductions over parietal regions. No hemispheric differences were detected.

    Conclusions:

    • P300 scalp topography effectively distinguishes Alzheimer's disease patients from healthy individuals.
    • The findings support the notion that P300 reflects activity from multiple neural generators, differentially affected in AD.
    • Altered P300 topography may serve as a valuable neurophysiological marker for Alzheimer's disease.